Peter Jo

1.4k total citations
28 papers, 924 citations indexed

About

Peter Jo is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Peter Jo has authored 28 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 9 papers in Cancer Research. Recurrent topics in Peter Jo's work include Colorectal Cancer Surgical Treatments (11 papers), Genetic factors in colorectal cancer (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Peter Jo is often cited by papers focused on Colorectal Cancer Surgical Treatments (11 papers), Genetic factors in colorectal cancer (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Peter Jo collaborates with scholars based in Germany, United States and Finland. Peter Jo's co-authors include Jochen Gaedcke, Tim Beißbarth, Marian Grade, Georg Emons, Michael Ghadimi, Hendrik A. Wolff, Thomas Ried, Β. Michael Ghadimi, Klaus Jung and Markus Schirmer and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Peter Jo

25 papers receiving 908 citations

Peers

Countries citing papers authored by Peter Jo

Since Specialization

Citations

This map shows the geographic impact of Peter Jo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Jo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Jo more than expected).

Fields of papers citing papers by Peter Jo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Jo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Jo. The network helps show where Peter Jo may publish in the future.

Co-authorship network of co-authors of Peter Jo

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Jo. A scholar is included among the top collaborators of Peter Jo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Jo. Peter Jo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integration molekularer, genetischer und chirurgischer Erkenntnisse in die Indikationsstellung zur präventiven Schilddrüsenchirurgie 2025 ·Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie ·(unknown), (unknown), (unknown), Michael Ghadimi, Peter Jo	0
2	METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial. 2024 ·Journal of Clinical Oncology ·Peter Jo, Michael Ghadimi, Uwe Pelzer, (unknown), Ralph Telgmann, Hanna Seppänen, Svein Olav Bratlie, Marc G. Besselink, Tim Friede, Jens T. Siveke	1
3	METAPANC-Intensified treatment in patients with oligometastatic pancreatic cancer-multimodal surgical treatment versus systemic chemotherapy alone: a prospective randomized multicenter phase III trial 2024 ·European Journal of Surgical Oncology ·Peter Jo, Michael Ghadimi, Uwe Pelzer, (unknown), Ralph Telgmann, Hanna Seppänen, Svein Olav Bratlie, Knut Jørgen Labori, (unknown), Tim Friede, Jens T. Siveke	0
4	Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO. 2024 ·Journal of Clinical Oncology ·Thorsten Oliver Goetze, Pompiliu Piso, (unknown), Claudia Pauligk, (unknown), (unknown), Disorn Sookthai, Sylvie Lorenzen, Michael Schenk, Armin Wiegering, Peter Jo, (unknown), J. P. Hölzen, Daniel E. Stange, Alexander Stein, Harald Schmalenberg, M. Senkal, Salah‐Eddin Al‐Batran	1
5	Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy 2022 ·British Journal of Cancer ·Georg Emons, Noam Auslander, Peter Jo, Julia Kitz, Azadeh Azizian, Yue Hu, Clemens F. Hess, Claus Röedel, Ulrich Sax, Gabriela Salinas, Philipp Stroebel, Frank Krämer, Tim Beißbarth, Marian Grade, Michael Ghadimi, Eytan Ruppin, Thomas Ried, Jochen Gaedcke	11
6	KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer 2020 ·PLoS ONE ·Peter Jo, Markus Bernhardt, Manuel Nietert, Alexander König, Azadeh Azizian, Markus Schirmer, Marian Grade, Julia Kitz, Kirsten Reuter‐Jessen, Michael Ghadimi, Philipp Ströbel, Hans‐Ulrich Schildhaus, Jochen Gaedcke	10
7	CA19-9 for detecting recurrence of pancreatic cancer 2020 ·Scientific Reports ·Azadeh Azizian, (unknown), T. Krause, Markus Bernhardt, Peter Jo, Alexander König, (unknown), Andreas Leha, Michael Ghadimi, Jochen Gaedcke	119
8	Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery 2017 ·Genes Chromosomes and Cancer ·Yue Hu, Jochen Gaedcke, Georg Emons, Tim Beißbarth, Marian Grade, Peter Jo, Meredith Yeager, Stephen J. Chanock, Hendrik A. Wolff, Jordi Camps, Β. Michael Ghadimi, Thomas Ried	82
9	Identification of Predictive Markers for Response to Neoadjuvant Chemoradiation in Rectal Carcinomas by Proteomic Isotope Coded Protein Label (ICPL) Analysis 2016 ·International Journal of Molecular Sciences ·Roland S. Croner, (unknown), Metodi V. Metodiev, Peter Jo, Michael Ghadimi, Vera Schellerer, (unknown), (unknown), Tilman T. Rau, Michael Stürzl, Elisabeth Naschberger, Klaus E. Matzel, Werner Hohenberger, Friedrich Lottspeich, Josef Kellermann	22
10	Heterogeneity of KRAS Mutation Status in Rectal Cancer 2016 ·PLoS ONE ·Peter Jo, Alexander König, Markus Schirmer, Julia Kitz, Lena‐Christin Conradi, Azadeh Azizian, Markus Bernhardt, Hendrik A. Wolff, Marian Grade, Michael Ghadimi, Philipp Ströbel, Hans‐Ulrich Schildhaus, Jochen Gaedcke	15
11	Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies 2016 ·Scientific Reports ·Peter Jo, Manuel Nietert, (unknown), Julia Kitz, (unknown), (unknown), Philipp Schüler, Hendrik A. Wolff, Josef Rüschoff, Philipp Ströbel, Marian Grade, Torsten Liersch, Tim Beißbarth, Michael Ghadimi, Ulrich Sax, Jochen Gaedcke	7
12	Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g 2013 ·Radiotherapy and Oncology ·(unknown), Melanie Spitzner, Frank Krämer, Xin Zhang, Peter Jo, Hendrik A. Wolff, Julia Kitz, Silke Kaulfuß, Tim Beißbarth, Matthias Dobbelstein, Michael Ghadimi, Marian Grade, Jochen Gaedcke	60
13	Molecular patterns in the evolution of serrated lesion of the colorectum 2012 ·International Journal of Cancer ·Timo Gaiser, (unknown), Daniela Hirsch, Jonathan Keith Killian, Jochen Gaedcke, Peter Jo, Immaculada Ponsa, Rosa Miró, Josef Rüschoff, Gerhard Seitz, Yue Hu, Jordi Camps, Thomas Ried	28
14	Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment 2011 ·Annals of Surgical Oncology ·Lena‐Christin Conradi, Annalen Bleckmann, Markus Schirmer, Thilo Sprenger, Peter Jo, Kia Homayounfar, Hendrik A. Wolff, (unknown), Peter Middel, Heinz Becker, Michael Ghadimi, Tim Beißbarth, Torsten Liersch	13
15	CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer 2011 ·Surgery ·Peter Jo, Klaus Jung, Marian Grade, Lena‐Christin Conradi, Hendrik A. Wolff, Julia Kitz, Heinz Becker, Josef Rüschoff, Arndt Hartmann, Tim Beißbarth, (unknown), Michael Ghadimi, Regine Schneider‐Stock, Jochen Gaedcke	38
16	Acute Toxicity of Radiochemotherapy in Rectal Cancer Patients: A Risk Particularly for Carriers of the TGFB1 Pro25 variant 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Markus Schirmer, (unknown), Margret Rave‐Fränk, Markus K. A. Herrmann, Steffen Hennies, Jochen Gaedcke, Lena‐Christin Conradi, Peter Jo, Tim Beißbarth, Clemens Friedrich Hess, Heinz Becker, Michael Ghadimi, Jürgen Brockmöller, Hans Christiansen, Hendrik A. Wolff	16
17	Mutated KRAS results in overexpression of DUSP4, a MAP‐kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas 2010 ·Genes Chromosomes and Cancer ·Jochen Gaedcke, Marian Grade, Klaus Jung, Jordi Camps, Peter Jo, Georg Emons, (unknown), Ulrich Sax, Markus Schirmer, H. Becker, Tim Beißbarth, Thomas Ried, Β. Michael Ghadimi	163
18	A new sensitivity-preferred strategy to build prediction rules for therapy response of cancer patients using gene expression data 2010 ·Computer Methods and Programs in Biomedicine ·Klaus Jung, Marian Grade, Jochen Gaedcke, Peter Jo, Lennart Opitz, Heinz Becker, B. Michael Ghadimi, Tim Beißbarth	6
19	Impact of RNA degradation on gene expression profiling 2010 ·BMC Medical Genomics ·Lennart Opitz, Gabriela Salinas-Riester, Marian Grade, Klaus Jung, Peter Jo, Georg Emons, B. Michael Ghadimi, Tim Beißbarth, Jochen Gaedcke	161
20	KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy 2009 ·Radiotherapy and Oncology ·Jochen Gaedcke, Marian Grade, Klaus Jung, Markus Schirmer, Peter Jo, (unknown), Hendrik A. Wolff, Markus K. A. Herrmann, Tim Beißbarth, Heinz Becker, Thomas Ried, Michael Ghadimi	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact